Precision Optics Corp (NASDAQ:POCI) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.
This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/.
View the webcast at https://app.webinar.net/l90v4RE3K1N
Summary
Precision Optics Corporation Inc reported record quarterly revenue of $8.7 million, doubling from the previous year and achieving positive adjusted EBITDA for the first time.
Key growth drivers included the aerospace and single-use cystoscope programs, with aerospace revenue reaching $3.6 million and cystoscope $2.2 million.
The company increased fiscal 2026 revenue guidance to $29-$31 million and adjusted EBITDA guidance to negative $2.5 to $2.7 million, reflecting strong production volumes and operational improvements.
Operational highlights included a 97% production yield for the aerospace program and significant yield improvements in the cystoscope line, with expectations to reach 95% yields soon.
Strategically, the company is focusing on micro optics capabilities and exploring growth opportunities in medical devices, defense, aerospace, and satellite communications.
The company completed a $10 million public offering to support growth plans, strengthening its balance sheet significantly.
Management expressed confidence in continued profitability growth, backed by a robust development pipeline and ongoing operational enhancements.
Full Transcript
OPERATOR
Good day and welcome to the Precision Optics reports Third Quarter Fiscal Year 2026 Financial Results Conference Call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press the star key, then one on your telephone keypad. To withdraw your question, please press the star key, then two. Please note this event is being recorded. I would now like to hand the conference over to Mr. Robert Bloom, Lipham Partners. Please go ahead.
Robert Bloom (Moderator)
All right, thank you, Darcy, and thank you to everyone joining the call today. As the operator mentioned, on today’s call we will Discuss Precision Optics third quarter fiscal year 2026 financial results and this for the period ended March 31, 2026. With us on the call representing the company today are Dr. Joe Forkey, Precision Optics Corporation Inc Chief Executive, and Wayne Cole, the company’s Chief Financial Officer. At the conclusion of today’s prepared remarks, we’ll open the call for a question and answer session again. If you dialed in through the traditional teleconference line as the operator indicated, please press star then one to ask a question. If you are listening through the webcast portal and would like to ask a question, you can submit your question through the Ask a Question feature in the webcast player. Before we begin with prepared remarks, we submit for the record the following statement. Statements made by the management team of Precision Optics during the course of this conference call may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 is amended and Section 21E of the Securities Exchange Act of 1934 is amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements describe future expectations, plans, results or strategies and are generally preceded by words such as may, future, plan, or planned, will or should, expected, anticipates, draft, eventually,, or projected. Listeners are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward looking statements, including the risks that actual results may differ materially from those projected in the forward looking statements as a result of various factors and other risks identified in the Company’s filings with the securities and Exchange Commission. All forward looking statements contained during this conference call speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company does not undertake any obligation to publicly update any forward looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. All right, with that said, let me turn the call over to Dr. Joe Forke, Chief Executive Officer, Precision Optics. Joe, please proceed.
Joe Forkey
Thank you Robert and thank you all for joining our call today. Last quarter we said Precision Optics Corporation Inc had strong production demand, but we’re still working through the challenges of scaling a much larger manufacturing business. In the third quarter revenue continued to grow and we began to see the payoff of the investments we’ve made in the last few quarters improving manufacturing processes and efficiency. Revenue was $8.7 million, a new quarterly record for Precision Optics and more than double the quarterly revenue of a year ago. More importantly, we achieved positive adjusted ebitda, a major milestone that that reflects both the strength of our core production programs, and the manufacturing improvements we’ve made over the last several quarters. Our two largest production programs continue to drive the business. Revenue from our top tier aerospace customer reached $3.6 million, a new record representing 44% sequential growth. This was the result of our investment in production capacity, now achieving improved efficiency. Production yields on this line have now increased to 97% consistently, a significant improvement from previous months that were typically in the 85 to 95% range. Because our customer has faced bottlenecks elsewhere in their deployment process, they have asked us to slow production against our existing backlog in Q1 and Q2 of fiscal 2027 with new orders expected for Q3. All indications are that we continue to be the sole source for this assembly and that the long term prospects for this program remain extremely high. Our single use Cystoscope program also contributed record revenue at $2.2 million in the third quarter, an all time high and representing approximately 10% sequential growth. More importantly, we have made dramatic progress in terms of production yields and costs. Here too, yields have increased to current rates above 90%, but not yet to the targeted 95% level which we expect to achieve in Q4. Beyond those two lead programs, we continue to advance newer programs, including our single use Ophthalmic Endoscope program supported by a $3.5 million follow on production order that we just announced last week. Our Ross Optical division also contributed significantly to the quarter’s improved bottom line. Revenue for Ross Optical was approximately $1.3 million compared to 1.0 million in Q2 and 0.8 million a year ago, representing 65% year over year growth. This is important because this business can support higher revenue without a proportional increase in headcount or other fixed costs, so incremental revenue contributes meaningfully to gross profit and adjusted ebitda. As a result of revenue growth and production improvements, our overall gross margin improved to 24% compared to 10% a year ago and 3% in Q2. While we still have work to do, the quarter showed that our operational improvements are beginning to translate into stronger financial performance as our production lines become more stable and the higher revenue levels leverage the manufacturing infrastructure we’ve built over recent quarters. The process and personnel updates that have driven the results are directly attributable to the change we made in our operating leadership, bringing on Joe Trout as Chief Operating Officer in October of last year. Joe has rebuilt the operations team, making changes where needed and empowering others to act with urgency to deliver more product with greatly improved efficiency. Joe and his team have made great progress in six months and I am confident we are seeing just the beginning of what they can accomplish going forward. We also strengthened our balance sheet in March through an oversubscribed $10 million public offering led by existing and new investors and including participation from directors and officers. This capital supports our growth plans and I want to thank all of our investors for their support. Given the strength of our results and our visibility into the remainder of the fiscal year, we are increasing fiscal 2026 revenue guidance to a range of 29 to $31 million compared to our previous guidance of 26 to $28 million. This represents 52 to 62% growth over fiscal 2025 revenue of $19.1 million. We are also increasing fiscal 2026 adjusted EBITDA guidance to a range of -$2.5 to -$2.7 million compared to our previous guidance of negative 2.5 to negative 3.0 million dollars. This translates into another quarter of roughly breakeven adjusted EBITDA in Q4. For comparison, adjusted EBITDA was -$3.7 million in fiscal 2025 and -$2.7 million in the first six months of the current fiscal year. As we look forward to Q4 and into fiscal 2027, we anticipate continued strong performance from our lead aerospace and cystoscopy production lines along with our quickly ramping single use ophthalmic endoscope line and with the highest backlog in many quarters, we believe that the recent increases in Ross Optical revenues are sustainable and will continue to contribute to positive margins and bottom line profitability going forward. In addition to the continuation of these strong revenue producing programs, we expect as many as five to six programs in the development pipeline to move to production in fiscal 2027. Three of these are scheduled to enter production over the next six months. A low volume single use device for small joint arthroscopy, an upper GI scope and a robotic surgery articulating rigid scope. While there are always timeline, yield and efficiency challenges when development programs are transitioning to production, our new operations team is deeply experienced and already working closely with the production and product development teams to ensure a smooth transfer and efficient drive to profitable volume production. This was a fantastic quarter for POC and we believe it’s just the beginning of leveraging our improved operational infrastructure with high revenues supported by our existing programs, new programs entering production today and new production slated for the next six to 12 months, along with a strong outlook for Ross Optical revenue and high variable margins, we believe the recent positive trends will continue to drive growing profitability.
Joe Forkey
In light of our operating performance and growing confidence in our production capabilities which contributed to our successful capital raise, we are thinking about strategic investments in our business in two specific areas. First, we are investing in capabilities required to become the leading production company in micro optics, including components and systems, especially those that are small and complex. We have learned through the ramp of the production programs I spoke to before that there are greater requirements to becoming a premier production company than we initially expected.
Joe Forkey
Investments go beyond simply increased production capacity. We require investment in quality assurance, manufacturing, engineering, supply chain management and other functions. We have made several of these out of necessity in recent months and will continue on this path to enhance and stabilize these capabilities to be well prepared for the anticipated ongoing increase in production volumes. Along with this, we continue to evaluate multiple options for potential updates to our manufacturing facilities.
Joe Forkey
Second, we want to grow within the markets we currently serve, all of which continue to exhibit strong growth trajectories able to support the substantial long term growth of poc. We participate in three primary markets medical device defense and aerospace and satellite communications. We have previously considered satellite communications and as part of aerospace, but have begun to treat that segment separately as we work to better understand market drivers and primary participants.
Joe Forkey
Medical Device, which remains our largest and most immediate opportunity, continues to move toward minimally invasive procedures, smaller imaging systems and single use devices. This aligns directly with our core strengths, particularly in micro optics and digital imaging. Market data continues to support these observations with recent reports estimating the disposable income market will grow at a compound annual growth rate of approximately 15 to 20% over the next 10 years. This is also where our Unity platform becomes important. Unity was designed to reduce development costs, time to market and execution risk to through a modular imaging architecture that can support reusable and single use endoscopic systems. As more customers look to bring advanced imaging products to market efficiently, we believe Unity can enhance our role as a development and production partner and provide a strong competitive advantage. Today we have one Unity program in our product development pipeline and are in discussions with four additional sales prospects today. The second major market is Defense aerospace which is increasingly driving optical systems to smaller size, weight and power or swap. We believe there are opportunities in a broad range of products from autonomous vehicles to directed energy weapons. Interest and budgets for these types of systems have increased substantially given the …
This post was originally published here
